GleamWall
中文EN

SLGL Sol-Gel Technologies Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1684693 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY68.0%
TTM net income YoY42.1%
TTM EPS YoY42.2%
Revenue 3-yr CAGR70.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-38.9%
Net margin-31.6%
FCF margin1.4%
EBITDA margin-38.3%

Returns

ROE-23.7%
ROA-18.6%
ROIC (approx.)-56.3%
Asset turnover0.59x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio4.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.05x
Accruals ratio-19.6%
Payout ratio—
Capex / revenue0.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$19.39M$11.54M
R&D expense$22.80M$17.80M
SG&A expense$4.18M$5.75M
Operating income-$7.54M-$12.01M
Income tax$0$0
Net income-$6.13M-$10.58M
EBITDA-$7.43M-$11.78M
EPS (basic)-2.19-3.79
EPS (diluted)-2.19-3.79
Weighted avg. shares (diluted)2.79M2.79M
Balance sheet
Cash & equivalents$11.03M$19.49M
Short-term investments$12.97M$4.42M
Receivables$1.97M$3.60M
Current assets$26.97M$31.30M
PP&E, net$140,000$202,000
Total assets$29.92M$35.85M
Current liabilities$6.17M$5.29M
Total liabilities$7.11M$7.00M
Shareholders' equity$22.81M$28.85M
Shares outstanding2.79M2.79M
Cash flow statement
Operating cash flow$322,000-$13.89M
Capital expenditure$47,000$2,000
Free cash flow$275,000-$13.89M
Investing cash flow-$8.58M$26.69M
Financing cash flow$6,000$0
Depreciation & amortization$109,000$233,000
Stock-based compensation$82,000$786,000

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.